IDBiologics is a human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases.
IDBiologics has raised $500K in total funding. The most recent round was Seed. The last funding was announced in May 2023.
IDBiologics's investors include Launch Tennessee, Acequia Capital (AceCap), Vanderbilt University, Flying Point Industries.
IDBiologics is headquartered in Nashville, United States.
IDBiologics is a human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases.
IDBiologics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"IDBiologics — Funding & Investors." VCBacked, May 23, 2023, https://www.vcbacked.co/company/idbiologics. Accessed August 14, 2026.
VCBacked. (2023). IDBiologics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/idbiologics
{{cite web |title=IDBiologics — Funding & Investors |url=https://www.vcbacked.co/company/idbiologics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated